GSK drops out of $20B race for Pfizer's consumer health unit — shares surge
GlaxoSmithKline has decided not to pursue an acquisition of Pfizer’s consumer health business after all, raising questions as to what they might spend on instead …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
